Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease

John J. O'Brien, Theodore M Bayless, Jeffrey A. Bayless

Research output: Contribution to journalArticle

Abstract

The efficacy and safety of therapy with azathioprine/6-mercaptopurine was studied in 78 patients with Crohn's disease. Mean duration of therapy was 1.6 years; 52 patients were treated ≥ 6 months. All patients were also on other antiinflammatory medications. Evaluations included self-assessment and physician's assessment of well-being, functional capacity, general clinical response, clinical activities indices (National Foundation for Ileitis and Colitis/International Organization for the Study of Inflammatory Bowel Disease and Harvey-Bradshaw), and achievement of specific therapeutic goals. General clinical condition improved in 70% of the patients. Median response time was 3 months. The average Harvey-Bradshaw score decreased 37% with therapy, and a decrease of ≥ 30% occurred in 66% of the subjects. An overall 72% achievement rate for specified therapeutic goals included controlling refractory disease, 73%; corticosteroid "sparing," 76%; and lessening fistulization, 63%. Nine patients got worse despite therapy. Adverse effects requiring discontinuation of therapy occurred in 10%, whereas dosages were briefly lowered for mild side effects in another 10%. This study demonstrates the effectiveness and safety of azathioprine/6-mercaptopurine in the majority of selected patients with chronic, unremitting, or steroid-requiring Crohn's disease.

Original languageEnglish (US)
Pages (from-to)39-46
Number of pages8
JournalGastroenterology
Volume101
Issue number1
StatePublished - 1991

Fingerprint

6-Mercaptopurine
Azathioprine
Crohn Disease
Therapeutics
Ileitis
Safety
Colitis
Inflammatory Bowel Diseases
Reaction Time
Adrenal Cortex Hormones
Anti-Inflammatory Agents
Steroids
Organizations
Physicians

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. / O'Brien, John J.; Bayless, Theodore M; Bayless, Jeffrey A.

In: Gastroenterology, Vol. 101, No. 1, 1991, p. 39-46.

Research output: Contribution to journalArticle

O'Brien, John J. ; Bayless, Theodore M ; Bayless, Jeffrey A. / Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. In: Gastroenterology. 1991 ; Vol. 101, No. 1. pp. 39-46.
@article{fad886af71a54387bacbb1b2494537ad,
title = "Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease",
abstract = "The efficacy and safety of therapy with azathioprine/6-mercaptopurine was studied in 78 patients with Crohn's disease. Mean duration of therapy was 1.6 years; 52 patients were treated ≥ 6 months. All patients were also on other antiinflammatory medications. Evaluations included self-assessment and physician's assessment of well-being, functional capacity, general clinical response, clinical activities indices (National Foundation for Ileitis and Colitis/International Organization for the Study of Inflammatory Bowel Disease and Harvey-Bradshaw), and achievement of specific therapeutic goals. General clinical condition improved in 70{\%} of the patients. Median response time was 3 months. The average Harvey-Bradshaw score decreased 37{\%} with therapy, and a decrease of ≥ 30{\%} occurred in 66{\%} of the subjects. An overall 72{\%} achievement rate for specified therapeutic goals included controlling refractory disease, 73{\%}; corticosteroid {"}sparing,{"} 76{\%}; and lessening fistulization, 63{\%}. Nine patients got worse despite therapy. Adverse effects requiring discontinuation of therapy occurred in 10{\%}, whereas dosages were briefly lowered for mild side effects in another 10{\%}. This study demonstrates the effectiveness and safety of azathioprine/6-mercaptopurine in the majority of selected patients with chronic, unremitting, or steroid-requiring Crohn's disease.",
author = "O'Brien, {John J.} and Bayless, {Theodore M} and Bayless, {Jeffrey A.}",
year = "1991",
language = "English (US)",
volume = "101",
pages = "39--46",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease

AU - O'Brien, John J.

AU - Bayless, Theodore M

AU - Bayless, Jeffrey A.

PY - 1991

Y1 - 1991

N2 - The efficacy and safety of therapy with azathioprine/6-mercaptopurine was studied in 78 patients with Crohn's disease. Mean duration of therapy was 1.6 years; 52 patients were treated ≥ 6 months. All patients were also on other antiinflammatory medications. Evaluations included self-assessment and physician's assessment of well-being, functional capacity, general clinical response, clinical activities indices (National Foundation for Ileitis and Colitis/International Organization for the Study of Inflammatory Bowel Disease and Harvey-Bradshaw), and achievement of specific therapeutic goals. General clinical condition improved in 70% of the patients. Median response time was 3 months. The average Harvey-Bradshaw score decreased 37% with therapy, and a decrease of ≥ 30% occurred in 66% of the subjects. An overall 72% achievement rate for specified therapeutic goals included controlling refractory disease, 73%; corticosteroid "sparing," 76%; and lessening fistulization, 63%. Nine patients got worse despite therapy. Adverse effects requiring discontinuation of therapy occurred in 10%, whereas dosages were briefly lowered for mild side effects in another 10%. This study demonstrates the effectiveness and safety of azathioprine/6-mercaptopurine in the majority of selected patients with chronic, unremitting, or steroid-requiring Crohn's disease.

AB - The efficacy and safety of therapy with azathioprine/6-mercaptopurine was studied in 78 patients with Crohn's disease. Mean duration of therapy was 1.6 years; 52 patients were treated ≥ 6 months. All patients were also on other antiinflammatory medications. Evaluations included self-assessment and physician's assessment of well-being, functional capacity, general clinical response, clinical activities indices (National Foundation for Ileitis and Colitis/International Organization for the Study of Inflammatory Bowel Disease and Harvey-Bradshaw), and achievement of specific therapeutic goals. General clinical condition improved in 70% of the patients. Median response time was 3 months. The average Harvey-Bradshaw score decreased 37% with therapy, and a decrease of ≥ 30% occurred in 66% of the subjects. An overall 72% achievement rate for specified therapeutic goals included controlling refractory disease, 73%; corticosteroid "sparing," 76%; and lessening fistulization, 63%. Nine patients got worse despite therapy. Adverse effects requiring discontinuation of therapy occurred in 10%, whereas dosages were briefly lowered for mild side effects in another 10%. This study demonstrates the effectiveness and safety of azathioprine/6-mercaptopurine in the majority of selected patients with chronic, unremitting, or steroid-requiring Crohn's disease.

UR - http://www.scopus.com/inward/record.url?scp=0025818064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025818064&partnerID=8YFLogxK

M3 - Article

C2 - 2044925

AN - SCOPUS:0025818064

VL - 101

SP - 39

EP - 46

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 1

ER -